Sanofi-Aventis CEO Plans Focus Switch From West To China
This article was originally published in PharmAsia News
France's Sanofi-Aventis told reporters it plans to take advantage of China's massive health-reform plan by expanding its Chinese business. To do so, Sanofi-Aventis is switching its emphasis away from reliance on blockbuster drugs in the developed world. The firm's CEO Christopher Viehbacher told reporters he will not be satisfied with just operating on the margins of China's healthcare system. Viehbacher said the company is looking for acquisitions, joint ventures or equity stakes with Chinese drug makers to give the company a large presence in basic drugs. (Click here for more - a subscription may be required
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.